Paper41374333
Quantitative CT Perfusion and Radiomics Reveal Complementary Markers of Treatment Response in HCC Patients Undergoing TACE.
Fezoulidis N and 4 others. Diagnostics (Basel), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Quantitative CT Perfusion and Radiomics Reveal Complementary Markers of Treatment Response in HCC Patients Undergoing TACE. Papers, record 41374333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41374333
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Quantitative CT Perfusion and Radiomics Reveal Complementary Markers of Treatment Response in HCC Patients Undergoing TACE.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26579733 | Radiomics: Images Are More than Pictures, They Are Data. | Radiology | 2016 | https://conductscience.org/library/papers/26579733 | PubMed |
| 2 | 29307467 | Hepatocellular carcinoma. | Lancet | 2018 | https://conductscience.org/library/papers/29307467 | PubMed |
| 3 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 4 | 20175034 | Current strategy for staging and treatment: the BCLC update and future prospects. | Semin Liver Dis | 2010 | https://conductscience.org/library/papers/20175034 | PubMed |
| 5 | 32154773 | The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. | Radiology | 2020 | https://conductscience.org/library/papers/32154773 | PubMed |
| 6 | 32233054 | Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. | J Magn Reson Imaging | 2020 | https://conductscience.org/library/papers/32233054 | PubMed |
| 7 | 33708638 | Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. | Liver Cancer | 2021 | https://conductscience.org/library/papers/33708638 | PubMed |
| 8 | 20175033 | Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. | Semin Liver Dis | 2010 | https://conductscience.org/library/papers/20175033 | PubMed |
| 9 | 34801630 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. | J Hepatol | 2022 | https://conductscience.org/library/papers/34801630 | PubMed |
| 10 | 22257792 | Radiomics: extracting more information from medical images using advanced feature analysis. | Eur J Cancer | 2012 | https://conductscience.org/library/papers/22257792 | PubMed |
| 11 | 36943423 | Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma. | Abdom Radiol (NY) | 2023 | https://conductscience.org/library/papers/36943423 | PubMed |
| 12 | 22086560 | Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. | Eur Radiol | 2012 | https://conductscience.org/library/papers/22086560 | PubMed |
| 13 | 38076381 | Role of Computed Tomography Perfusion in Patients with Liver Cirrhosis and Hepatocellular Carcinoma. | J Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/38076381 | PubMed |
| 14 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 15 | 17517931 | Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. | Radiology | 2007 | https://conductscience.org/library/papers/17517931 | PubMed |
| 16 | 39086938 | Enhancing prognostic prediction in hepatocellular carcinoma post-TACE: a machine learning approach integrating radiomics and clinical features. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39086938 | PubMed |
| 17 | 35896687 | Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. | Cardiovasc Intervent Radiol | 2022 | https://conductscience.org/library/papers/35896687 | PubMed |
| 18 | 34745952 | Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning. | Front Oncol | 2021 | https://conductscience.org/library/papers/34745952 | PubMed |
| 19 | 30887739 | Hepatocellular Carcinoma: Texture Analysis of Preoperative Computed Tomography Images Can Provide Markers of Tumor Grade and Disease-Free Survival. | Korean J Radiol | 2019 | https://conductscience.org/library/papers/30887739 | PubMed |
| 20 | 34918174 | Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study. | Abdom Radiol (NY) | 2022 | https://conductscience.org/library/papers/34918174 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41374333
GET https://conductscience.org/api/papers/v1/41374333/references?page=2